Wendell Amy McBride

SEC source: 0001127602-24-015465 · form4.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,544

Underlying: Common Stock · 1,980 shares

Expires 2034-05-13

F1 · derivative.exercise_price: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.

F3 · derivative.exercise_date: The RSUs shall fully vest on March 27, 2026, subject to continued service through the vesting date.

SEC source: 0001127602-24-015465 · form4.xml · derivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,564

Underlying: Common Stock · 3,564 shares

Expires 2034-05-13

F1 · derivative.exercise_price: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.

F2 · derivative.exercise_date: The RSUs shall fully vest on May 13, 2025, subject to continued service through the vesting date.

SEC source: 0001062993-24-009787 · form4.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,876

F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.

F2 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001127602-24-009458 · form4.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,536

Underlying: Common Stock · 4,536 shares

Expires 2034-03-07

F3 · derivative.exercise_date: Options become exercisable on the date of the 2025 Annual Meeting of Stockholders.

SEC source: 0001127602-24-009458 · form4.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,730

F1 · shares: Represents restricted stock units which vest on the date of the 2025 Annual Meeting of Stockholders and are settled in shares of common stock.

F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis.

SEC source: 0000805928-23-000124 · wf-form4_169420440642854.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,342

SEC source: 0000805928-23-000122 · wf-form4_169408287703094.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,904

Underlying: Common Stock · 11,904 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting.

F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting.

SEC source: 0000805928-23-000122 · wf-form4_169408287703094.xml · derivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,436

Underlying: Common Stock · 20,436 shares

Expires 2033-09-01

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting.

SEC source: 0000805928-23-000060 · wf-form4_168600385814712.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,459 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date.

SEC source: 0000805928-23-000060 · wf-form4_168600385814712.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,342

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2023.

SEC source: 0000805928-23-000053 · wf-form4_168426906043269.xml · derivative · entry 4

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2023-09-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-23-000053 · wf-form4_168426906043269.xml · derivative · entry 3

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2023-09-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-23-000053 · wf-form4_168426906043269.xml · nonDerivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,883

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-23-000053 · wf-form4_168426906043269.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,133

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-23-010216 · form4.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,894

F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.

SEC source: 0001127602-23-009879 · form4.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,210

Underlying: Common Stock · 4,210 shares

Expires 2033-03-09

F3 · derivative.exercise_date: Options become exercisable on the date of the 2024 Annual Meeting of Stockholders.

SEC source: 0001127602-23-009879 · form4.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,158

F1 · kind: Represents restricted stock units which vest on the date of the 2024 Annual Meeting of Stockholders and are settled in shares of common stock.

F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis.

SEC source: 0000805928-22-000065 · wf-form4_165428697291546.xml · derivative · entry 4

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,459

Underlying: Common Stock · 6,459 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

F4 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-22-000065 · wf-form4_165428697291546.xml · derivative · entry 3

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,811

Underlying: Common Stock · 11,811 shares

Expires 2032-06-01

F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-22-000065 · wf-form4_165428697291546.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,036 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.

SEC source: 0000805928-22-000065 · wf-form4_165428697291546.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,133

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2022.

SEC source: 0001062993-22-011693 · form4.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,168

F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc. (BII), subject to the terms and conditions of the applicable grant.

F2 · balance_after: The amount of securities beneficially owned include 42.90 shares acquired under the BII Dividend Reinvestment Plan (DRIP) between April 1, 2019 and April 1, 2021.

SEC source: 0001127602-22-009149 · form4.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,293

Underlying: Common Stock · 5,293 shares

Expires 2032-03-10

F3 · derivative.exercise_date: Options become exercisable on the date of the 2023 Annual Meeting of Stockholders.

SEC source: 0001127602-22-009149 · form4.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,693

F1 · shares: Represents restricted stock units which vest on the date of the 2023 Annual Meeting of Stockholders and are settled in shares of common stock.

F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis.

SEC source: 0000805928-21-000111 · wf-form4_162275483321636.xml · derivative · entry 4

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,036

Underlying: Common Stock · 3,036 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-21-000111 · wf-form4_162275483321636.xml · derivative · entry 3

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,030

Underlying: Common Stock · 6,030 shares

Expires 2031-06-01

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-21-000111 · wf-form4_162275483321636.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,173 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: This reflects the number of restricted stock units that became vested as of June 1, 2021.

F2 · derivative.expiration_date: This reflects the number of restricted stock units that became vested as of June 1, 2021.

SEC source: 0000805928-21-000111 · wf-form4_162275483321636.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,097

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001400568-21-000001 · edgar.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,685

Underlying: Common Stock, $1 par value · 5,685 shares

Expires 2031-05-04

F2 · derivative.exercise_date: The reporting person received a grant of fully vested Company stock options, subject to the terms and conditions of the applicable grant.

SEC source: 0001400568-21-000001 · edgar.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,365

F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc. ("Company"), subject to the terms and conditions of the applicable grant.

SEC source: 0001127602-21-010632 · form4.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,055

Underlying: Common Stock · 5,055 shares

Expires 2031-03-11

F3 · derivative.exercise_date: Option becomes exercisable on the date of the 2022 Annual Meeting of Stockholders.

SEC source: 0001127602-21-010632 · form4.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,128

F1 · shares: Represents restricted stock units which vest on the date of the 2022 Annual Meeting of Stockholders and are settled in shares of common stock.

F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis.

SEC source: 0001179110-20-009634 · edgar.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,924

F1 · shares: This reflects the number of restricted stock units that became vested as of September 3, 2020.

SEC source: 0001179110-20-006910 · edgar.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,115

Underlying: Common Stock · 4,115 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units.

F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units.

SEC source: 0001179110-20-006910 · edgar.xml · derivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,807

Underlying: Common Stock · 16,807 shares

Expires 2030-06-01

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units.

SEC source: 0001179110-20-007283 · edgar.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,173

Underlying: Common Stock · 6,173 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units.

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

F3 · derivative.underlying_shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units.

F3 · balance_after: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units.

SEC source: 0001179110-20-007283 · edgar.xml · derivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,605

Underlying: Common Stock · 12,605 shares

Expires 2030-06-01

F3 · shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units.

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

F3 · derivative.underlying_shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units.

F3 · balance_after: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units.

SEC source: 0001400568-20-000002 · edgar.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,293

Underlying: Common Stock, $1 par value · 5,293 shares

Expires 2030-05-03

F2 · derivative.exercise_date: The reporting person received a grant of fully vested Company stock options, subject to the terms and conditions of the applicable grant.

SEC source: 0001400568-20-000002 · edgar.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,249

F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc. ("Company"), subject to the terms and conditions of the applicable grant.

SEC source: 0001400568-20-000001 · edgar.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,150

SEC source: 0001127602-20-009975 · form4.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,322

Underlying: Common Stock · 7,322 shares

Expires 2030-03-05

F3 · derivative.exercise_date: Options become exercisable on the date of the 2021 Annual Meeting of Stockholders.

SEC source: 0001127602-20-009975 · form4.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,650

F1 · shares: Represents restricted stock units which vest on the date of the 2021 Annual Meeting of Stockholders and are settled in shares of common stock.

F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis.

SEC source: 0001179110-19-010094 · edgar.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,591

Underlying: Common Stock · 2,591 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units.

F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units.

SEC source: 0001179110-19-010094 · edgar.xml · derivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,710

Underlying: Common Stock · 10,710 shares

Expires 2029-09-03

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units.

SEC source: 0001179110-19-007686 · edgar.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,333

F1 · shares: The reporting person purchased these shares in her individual capacity in the open market and not through any directed share or other formal program.

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.20 to $20.26. The reporting person undertakes to provide to Axogen, Inc., any security holder of Axogen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0001400568-19-000003 · edgar.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,138

Underlying: Common Stock, $1 par value · 6,138 shares

Expires 2029-05-07

F2 · derivative.exercise_date: The reporting person received a grant of fully vested Company stock options, subject to the terms and conditions of the applicable grant.

SEC source: 0001400568-19-000003 · edgar.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,650

F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc. (the "Company"), subject to the terms and conditions of the applicable grant.

SEC source: 0001127602-19-010917 · form4.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,523

Underlying: Common Stock · 6,523 shares

Expires 2029-03-07

F3 · derivative.exercise_date: Options become exercisable on the date of the 2020 Annual Meeting of Stockholders

SEC source: 0001127602-19-010917 · form4.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,433

F1 · shares: Represents restricted stock units which vests on the date of the 2020 Annual Meeting of Stockholders and are settled in shares of common stock.

F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis.

SEC source: 0001400568-19-000002 · edgar.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,444

F1 · shares: The reporting person received a grant of 444 fully vested shares of common stock of Baxter International Inc. subject to the terms and conditions of the applicable grant.

F1 · price: The reporting person received a grant of 444 fully vested shares of common stock of Baxter International Inc. subject to the terms and conditions of the applicable grant.